Breton Hill Capital Ltd.'s Q2 2017 vs. Q3 2017: A Look at the Fund's Holdings Shifts

Investors in hedge funds and institutional investors alike are always interested in the activities of the top players in the industry. One such player is Breton Hill Capital Ltd., which recently released its Q2 2017 vs. Q3 2017 13F Holdings Comparison report. The report details the fund's latest moves in the market, including increases and decreases in holdings of specific issuers. In this blog post, we'll take a closer look at the report, and analyze some of the most notable shifts in holdings.

Introduction

Breton Hill Capital Ltd. is a premier investment management firm that manages a diverse range of strategies, including quantitative and systematic trading strategies, high-frequency trading, and traditional long/short equity strategies. The firm specializes in the use of cutting-edge technology and data science to help its clients achieve superior returns in the financial markets. As of its most recent 13F filing, the fund had a total value of $1.71 billion and held positions in 185 different stocks.

Main Body

Breton Hill Capital Ltd.'s Q2 2017 vs. Q3 2017 13F Holdings Comparison report provides a comprehensive overview of the fund's activities during the quarter, including holdings changes, new positions, and closed-out positions. Here are some of the most notable changes in holdings:

- LyondellBasell Industries NV: Breton Hill Capital Ltd. increased its position in this chemical company by 17.7%, from 128,888 shares to 146,555 shares, and the value of the position increased by 33.5%, from $10.88 million to $14.52 million. The company recently reported strong third-quarter earnings, driven by higher volumes, better pricing, and lower costs.

- Pfizer Inc.: The fund increased its position in this pharmaceutical company by 5%, from 385,937 shares to 405,872 shares, and the value of the position increased by 11.8%, from $12.96 million to $14.49 million. Pfizer recently announced that its breast cancer treatment, Ibrance, had been approved by the European Commission, which should help the company expand its sales.

- Ford Motor Co.: Breton Hill Capital Ltd. increased its position in Ford by 10.4%, from 1,045,401 shares to 1,155,344 shares, and the value of the position increased by 18.2%, from $11.70 million to $13.83 million. The company recently reported third-quarter earnings that beat estimates, driven by strong demand for its trucks and SUVs.

- AbbVie Inc.: The fund increased its position in AbbVie, a biopharmaceutical company, by 6%, from 143,225 shares to 151,868 shares, and the value of the position increased by 29.9%, from $10.38 million to $13.50 million. The company recently reported strong third-quarter earnings, driven by solid growth in its Humira franchise.

- International Business Machines Corp.: Breton Hill Capital Ltd. increased its position in IBM by 820.6%, from 9,035 shares to 83,244 shares, and the value of the position increased by 768.8%, from $1.39 million to $12.08 million. The company recently reported third-quarter earnings that beat estimates, driven by strong demand for its cloud and cognitive solutions.

Conclusion

Breton Hill Capital Ltd.'s Q2 2017 vs. Q3 2017 13F Holdings Comparison report provides valuable insights into the fund's latest moves in the financial markets. Although the report covers a range of holdings changes, some of the most notable include the fund's increased positions in LyondellBasell Industries, Pfizer, Ford, AbbVie, and IBM. Investors who are interested in following the activities of top players in the industry should keep an eye on Breton Hill Capital Ltd.'s future 13F filings, as they provide a glimpse into the fund's investment strategy and stock-picking prowess.